Genexine, a South Korean novel drug developer, out-licensed five long acting biologic drug candidates to Tasly Pharma of Tianjin in a deal worth up to $100 million. Genexine will receive $20 million upfront and up to $80 million in development and commercial milestones, and Tasly will also pay royalties on sales. Tasly will own China rights to three Genexine products in clinical or near-clinical stage and global rights for two additional candidates in preclinical development. A Tasly subsidiary, Tasgen, will develop the Genexine products.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
